27 August 2015

ASX ANNOUNCEMENT

APPENDIX 4E - Alteration

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), announce that further to the release of Appendix 4E on 26 August 2015 an amended version has been resubmitted to the ASX.

Changes as follows:

Page one – The original document had brackets around the revenue numbers. These have now been deleted.

Cherrell Hirst AO
Chairman

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au
1 Current Financial Period Ended: 30 June 2015
   Previous Corresponding Reporting Period: 30 June 2014

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2015 ("2015 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

2 Results for announcement to the market

<table>
<thead>
<tr>
<th></th>
<th>Current reporting period</th>
<th>Previous corresponding period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue from ordinary activities</td>
<td>$4,927</td>
<td>$3,578</td>
</tr>
</tbody>
</table>

Increase (decrease) in revenue ($000): $1,349
Percentage increase (decrease): 38%

Note: Revenue related to goods and services increased for the year ended 30 June 2015 to $4.9 million (2014 $3.6 million), an increase of $1.3 million year over year. The change by operating segment was an increase of $0.5 million in medical, and a $0.8 million increase in test & measurement. The $0.5 million increase in the medical segment was due to a $0.1 million increase in body composition and veterinary products, while total lymphoedema product revenue for the Group increased by $0.4 million, or 28% year over year.

Profit/(loss) from ordinary activities after tax attributable to members:

<table>
<thead>
<tr>
<th></th>
<th>Current reporting period</th>
<th>Previous corresponding period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit/(loss) from ordinary activities after tax attributable to members</td>
<td>(14,797)</td>
<td>(7,935)</td>
</tr>
</tbody>
</table>

Increase/(decrease) in profit from ordinary activities after tax attributable to members ($000): $6,862
Percentage increase/(decrease): -86%

Note: Refer to the Directors’ Report for a more extensive analysis; however, in summary, in addition to the increase in revenue above:
- salaries and benefits expense increased by $4.4 million
- research and development expenses increased by $0.6 million
- consultants and professional fees increased by $0.5 million
- advertising and promotion expense increased by $0.8 million
- travel expense increased by $0.5 million

Net profit/(loss) for the period attributable to members:

<table>
<thead>
<tr>
<th></th>
<th>Current reporting period</th>
<th>Previous corresponding period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net profit/(loss) for the period attributable to members</td>
<td>(14,797)</td>
<td>(7,935)</td>
</tr>
</tbody>
</table>

Increase/(decrease) in net profit for the period attributable to members ($000): $6,862
Percentage increase/(decrease): -86%

Note: Refer to 2.2 above and to the Directors’ Report in the 2015 Financial Report.

3 Dividends

3.1 Dividends
   Nil

   There were no dividends declared and paid during the reporting period on ordinary shares.
   There were no dividends proposed and not yet recognised as a liability during the reporting period.

3.2 Dividend Record Date
   Not applicable
4 Financial Statements

4.1 Statement of comprehensive income

4.2 Statement of financial position

4.3 Statement of cash flows

4.4 Statement of retained earnings

5 Net tangible assets per security

<table>
<thead>
<tr>
<th></th>
<th>Current reporting period</th>
<th>Previous corresponding period</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Net tangible assets ($000)</td>
<td>32,429</td>
<td>11,567</td>
</tr>
<tr>
<td>Issued share capital at reporting date ($000)</td>
<td>147,349</td>
<td>116,593</td>
</tr>
<tr>
<td>Number of shares on issue at reporting date</td>
<td>293,287,840</td>
<td>238,672,802</td>
</tr>
<tr>
<td>Net tangible assets per security</td>
<td>$ 0.11</td>
<td>$ 0.05</td>
</tr>
</tbody>
</table>

6 Earnings per security

<table>
<thead>
<tr>
<th></th>
<th>Current reporting period</th>
<th>Previous corresponding period</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS)</td>
<td>268,288,850</td>
<td>195,605,935</td>
</tr>
</tbody>
</table>

| Loss per share from continued operations | Basic EPS | $ | - | $ | - |
| Loss per share from profit attributable to ordinary shares | Basic EPS | $ | - | $ | - |

Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented.

Refer to Note 1 - Earnings per share in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to EPS for the current reporting period.

7 Acquisitions and divestments
There were no entities over which control has been gained or lost during the reporting period.

8 Foreign entities
Not applicable.

9 Associates and joint ventures
Not applicable.

10 Commentary on results for the financial year

11 Results of segments
Refer to Note 3 - Segment reporting in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to segment results for the current reporting period.

12 Audited Report
The report is based on audited accounts which are not subject to dispute, modification, or qualification.